Evidence map›Paper›PMID 29362915›Full record

ArticleJournal of cancer research and clinical oncology2018

Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer.

Francesca Sanguedolce, Antonella Cormio, Paolo Massenio, Maria C Pedicillo, Simona Cagiano, Francesca Fortunato, Beppe Calò, Giuseppe Di Fino, Giuseppe Carrieri, Pantaleo Bufo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francesca SanguedolceDepartment of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Antonella CormioDepartment of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Via E. Orabona 4, 70124, Bari, BA, Italy.
Paolo MassenioDepartment of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Maria C PedicilloDepartment of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Simona CagianoDepartment of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Francesca FortunatoDepartment of Epidemiology and Public Health, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Beppe CalòDepartment of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Giuseppe Di FinoDepartment of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Giuseppe CarrieriDepartment of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Pantaleo BufoDepartment of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy.
Luigi CormioDepartment of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. luigicormio@libero.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe identification of factors predicting the outcome of stage T1 high-grade bladder cancer (BC) is a major clinical issue.

methodsWe performed immunohistochemistry to assess the role of human epidermal growth factor receptor-2 (HER-2) and microsatellite instability (MSI) factors MutL homologue 1 (MLH1) and MutS homologue 2 (MSH2) in predicting recurrence and progression of T1 high-grade BCs having undergone transurethral resection of bladder tumor (TURBT) alone or TURBT + intravesical instillations of bacillus Calmette-Guerin (BCG).

resultsHER-2 overexpression was a significant predictor of disease-free survival (DFS) in the overall as well as in the two patients' population; as for progression-free survival (PFS), it was significant in the overall but not in the two patients' population. MLH1 was an independent predictor of PFS only in patients treated with BCG and MSH2 failed to predict DFS and PFS in all populations. Most importantly, the higher the number of altered markers the lowers the DFS and PFS. In multivariate Cox proportional-hazards regression analysis, the number of altered molecular markers and BCG treatment were significant predictors (p = 0.0004 and 0.0283, respectively) of DFS, whereas the number of altered molecular markers was the only significant predictor (p = 0.0054) of PFS.

conclusionsAltered expression of the proto-oncogene HER-2 and the two molecular markers of genetic instability MLH1 and MSH2 predicted T1 high-grade BC outcome with the higher the number of altered markers the lower the DFS and PFS. These findings provide grounds for further testing them in predicting the outcome of this challenging disease.

Indexed as

AgedAge FactorsBCG VaccineErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMutL Protein Homolog 1MutS Homolog 2 ProteinNeoplasm GradingPrognosisProto-Oncogene MasTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMAS1 protein, humanMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinProto-Oncogene MasHER-2ImmunohistochemistryMLH1MSH2Non-muscle-invasive bladder cancerPrognosis

Identifiers

PMID29362915
PMCPMC11813396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.